Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

SESSION 1

Precision For All:

Global Access, Real Cases, and Implementation Science

Results and Future Direction from WIN’s Data Science Paper

Gerald Batist, MD, Director, Segal Cancer Centre, Jewish General Hospital; Director, McGill Centre for Translational Research in Cancer; Professor, Department of Oncology, McGill University

When Precision Gets Personal: WIN Consortium International Molecular Tumor Board Live

Wafik S. El-Deiry, MD, PhD, FACP, Chair, WIN Consortium, Director, Legorreta Cancer Center Brown University, Director, Joint Program in Cancer Biology, Brown University and Brown University Health; Associate Dean, Oncologic Sciences, Warren Alpert Medical School, Brown University; Attending Physician, Hematology/Oncology, Brown University Health Mencoff Family University; Professor of Medical Science, Professor of Pathology and Laboratory Medicine, Brown University; Professor, American Cancer Society Research Professor

Razelle Kurzrock, MD, FACP, Chief Medical Officer, WIN Consortium; Professor of Medicine, Associate Director, Clinical Research, Linda T. and John A. Mellowes Endowed Chair of Precision Oncology, MCW Cancer Center and Linda T. & John A. Mellowes Center for Genomic Sciences and Precision Medicine

Notes from Live Tumor Board from Live Tweets

Tumor board Live… Molecular profiling great for identifying synthetic lethal combinations work very well… Many oncologist not accepting recommendations of molec tumor board

SESSION 2

Expanding the Precision Frontier

Precision Oncology in the Immunotherapy Era: Biomarkers and Clinical Trial Innovation

Lillian Siu, MD, President, AACR 2025-2026; Director, Phase I Clinical Trials Program; Co-Director, Robert and Maggie Bras and Family Drug Development Program Clinical Lead, Tumor Immunotherapy Program; BMO Chair, Precision Cancer Genomics, Princess Margaret Cancer Centre Professor of Medicine, University of Toronto

• Princess Margaret CC went to Merck got pembrolizumab from them but built a team platform of clinicians and scientists to work on INSPIRE trial
• $11 million of grants, 13 major papers, great team science
• did ctDNA from liquid biopsy and also looked at methylation patterns in cfDNA
• looked at IFN stimulation and outcome to pembrolizumab
• retro transposable elements found in INSPIRE program, maybe a predictor of immune sensitivity
• they were able to correlate some of their findings with spatial omics
• using spatial data they could look at hot versus cold head and neck cancer
•  factors for response to immunotherapy: TMB, t cell infiltrate,  PDL1 etc
• using AI with IHC slides as well as NGS data sets
• as clinical trials become multiomics and AI with multiomics platforms data sharing will be critical for success

The Microbiome and Its Role in Cancer Development and Treatment Response

Sabine Hazan, MD, CEO, Ventura Clinical Trials; CEO, Progenabiome

• microbiome research at the infancy so we don’t know much when comes to oncology
• we need to compare microbiome between persons using NGS and other omics
• we all have different microbiome even though microbiome ‘healthy’
• lots of factors affect microbiome including surgery
• families are similar in their microbiome but when looking at Alzheimers there are differences
• first lab to find whole COVID in the stools
• virus was different in different people, difference spike proteins. Virus mutates from lung to stool (gut)
• in intrafamily patients had different microbiome upon COVID infection
• bifodobacteria was found as a major part of microbiome altered in COVID but also lots of other diseases
• lots of examples of host microbial symbiosis
• they had an instance with throat tumor treated with microbiome and tumor receded without chemo
• in a glioblastoma microbiome adjustment helped but changed positive response to immunotherapy